<DOC>
	<DOC>NCT01602367</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.</brief_summary>
	<brief_title>Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Qualifying seated blood pressure between ≥90 and ≤105 mmHg diastolic AND ≤155 mmHg systolic Mean 24hour diastolic blood pressure ≥85 mmHg Body mass index (BMI) ≥27 kg/m2 If receiving an oral antihyperglycemic medication or a cholesterol lowering medication, receiving a stable dose for at least 6 weeks History of Cushing's disease or syndrome, or Addison's disease Glycosylated hemoglobin (HbA1c) ≥10% Cerebrovascular insult, unstable angina, or myocardial infarction (MI) within 6 months History of impaired renal or hepatic function BMI ≥50 kg/m2 Any injectable antihyperglycemic agent (such as insulin) within 16 weeks Currently receiving more than one class of antihypertensive agents within 4 weeks Daily use of nonsteroidal antiinflammatory agents within 1 week Use of androgen medications, including topical preparations, within 6 weeks Diagnosis or history of breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>